Revenue Hit a Record ₹9,150 Crore, Up 16% From ₹7,868 Crore, Driven by Broad-based Growth Across Business Segments

Hyderabad-based Aurobindo Pharma posted a 25% rise in net profit to ₹1,032 crore for the first quarter ended June 30, 2026, compared with ₹824 crore a year earlier. Revenue hit a record ₹9,150 crore, up 16% from ₹7,868 crore, driven by broad-based growth across business segments. K. Nithyananda Reddy, Vice-Chairman and Managing Director, said the company started FY27 on a strong note through disciplined execution and operational excellence, adding that its resilient model and strategic investments position it for long-term growth.